{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Jones RT"],"funding":["National Cancer Institute (NCI)","Anschutz Family Foundation","National Cancer Institute","Erasmus Medisch Centrum (EMC)","NCI NIH HHS","National Institute of General Medical Sciences","Finnish Cancer Institute (Suomen syöpälaitos)","NIGMS NIH HHS","National Institute of General Medical Sciences (NIGMS)","Erasmus Medisch Centrum","Finnish Cancer Institute"],"pagination":["1699-1718"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11094426"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["84(10)"],"pubmed_abstract":["There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which is used in primary and metastatic settings in many cancer types. In bladder cancer, platinum-based chemotherapy leads to better outcomes in a subset of patients when used in the neoadjuvant setting or in combination with immunotherapy for advanced disease. Despite such promising results, extending the benefits of platinum drugs to a greater number of patients is highly desirable. Using the multiomic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified puromycin-sensitive aminopeptidase (NPEPPS) as a driver of cisplatin resistance. NPEPPS depletion sensitized resistant bladder cancer cells to cisplatin in vitro and in vivo. C"],"journal":["Cancer research"],"pubmed_title":["NPEPPS Is a Druggable Driver of Platinum Resistance."],"pmcid":["PMC11094426"],"funding_grant_id":["R01 CA180175","P30 CA046934","CA268055","107088","CA046934","T32 GM008497","111296","CA180175","R01 CA268055","GM008497","T32 GM007635","GM007635"],"pubmed_authors":["Vekony H","Jones RT","Mahmoudi T","Xander N","Romal S","Goodspeed A","Feldman LE","Zuiverloon TCM","Layer R","Clambey ET","Costello JC","Joshi M","Araki SP","Scholtes M","Jean A","Kan TW","Theodorescu D","Mohapatra S","Tilton CB","Parker SJ","Akbarzadeh M","Deiter C","Javaid M","Orman MV","Laajala TD"],"additional_accession":[]},"is_claimable":false,"name":"NPEPPS Is a Druggable Driver of Platinum Resistance.","description":"There is an unmet need to improve the efficacy of platinum-based cancer chemotherapy, which is used in primary and metastatic settings in many cancer types. In bladder cancer, platinum-based chemotherapy leads to better outcomes in a subset of patients when used in the neoadjuvant setting or in combination with immunotherapy for advanced disease. Despite such promising results, extending the benefits of platinum drugs to a greater number of patients is highly desirable. Using the multiomic assessment of cisplatin-responsive and -resistant human bladder cancer cell lines and whole-genome CRISPR screens, we identified puromycin-sensitive aminopeptidase (NPEPPS) as a driver of cisplatin resistance. NPEPPS depletion sensitized resistant bladder cancer cells to cisplatin in vitro and in vivo. C","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-01T05:25:57.363Z","creation":"2025-08-27T03:08:53.289Z"},"accession":"S-EPMC11094426","cross_references":{"pubmed":["38535994"],"doi":["10.1158/0008-5472.CAN-23-1976"]}}